dc.contributor.author |
Patjana T. |
|
dc.contributor.author |
Jantaharn P. |
|
dc.contributor.author |
Katrun P. |
|
dc.contributor.author |
Mongkolthanaruk W. |
|
dc.contributor.author |
Suwannasai N. |
|
dc.contributor.author |
Senawong T. |
|
dc.contributor.author |
Tontapha S. |
|
dc.contributor.author |
Amornkitbumrung V. |
|
dc.contributor.author |
McCloskey S. |
|
dc.date.accessioned |
2022-03-10T13:17:26Z |
|
dc.date.available |
2022-03-10T13:17:26Z |
|
dc.date.issued |
2021 |
|
dc.identifier.issn |
14786419 |
|
dc.identifier.other |
2-s2.0-85071024282 |
|
dc.identifier.uri |
https://ir.swu.ac.th/jspui/handle/123456789/17539 |
|
dc.identifier.uri |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85071024282&doi=10.1080%2f14786419.2019.1652292&partnerID=40&md5=38a2f447c8d906b70394b5545a002d26 |
|
dc.description.abstract |
The ongoing search for anti-cancer agents from microorganisms led to the isolation of four new compounds including 6-ethyl-8-hydroxy-4H-chromen-4-one (1), 6-ethyl-7,8-dihydroxy-4H-chromen-4-one (2), (3S)-3,4-dihydro-8-hydroxy-7-methoxy-3-methylisocoumarin (3) and (3S)-3,4-dihydro-5,7,8-trihydroxy-3-methylisocoumarin (4), together with eleven known compounds (5–15) from Xylaria sp. SWUF09-62 fungus. The chemical structures were deduced from IR, 1D and 2D NMR, and MS data. The absolute configurations of 3 and 4 were determined by ECD experiment. Compounds 2 and 4 indicated possible chemo-prevention and chemo-therapeutic properties, exhibited anti-inflammatory properties by reducing nitric oxide production in LPS-stimulated RAW264.7 cells (IC50 = 1.57 ± 0.25 and 3.02 ± 0.27 μg/mL) and cytotoxicity against HT29 cells (IC50 = 16.46 ± 0.48 and 97.78 ± 7.14 μg/mL). © 2019 Informa UK Limited, trading as Taylor & Francis Group. |
|
dc.subject |
3,4 dihydro 5,7,8 trihydroxy 3 methylisocoumarin |
|
dc.subject |
3,4 dihydro 8 hydroxy 7 methoxy 3 methylisocoumarin |
|
dc.subject |
6 ethyl 7,8 dihydroxy 4h chromen 4 one |
|
dc.subject |
6 ethyl 8 hydroxy 4h chromen 4 one |
|
dc.subject |
antiinflammatory agent |
|
dc.subject |
cytotoxic agent |
|
dc.subject |
diclofenac |
|
dc.subject |
nitric oxide |
|
dc.subject |
unclassified drug |
|
dc.subject |
antiinflammatory agent |
|
dc.subject |
antineoplastic agent |
|
dc.subject |
biological product |
|
dc.subject |
lipopolysaccharide |
|
dc.subject |
antiinflammatory activity |
|
dc.subject |
Article |
|
dc.subject |
cancer cell |
|
dc.subject |
carbon nuclear magnetic resonance |
|
dc.subject |
cell viability |
|
dc.subject |
chemical structure |
|
dc.subject |
chemoprophylaxis |
|
dc.subject |
controlled study |
|
dc.subject |
cytotoxicity |
|
dc.subject |
fungus |
|
dc.subject |
IC50 |
|
dc.subject |
infrared spectroscopy |
|
dc.subject |
macrophage |
|
dc.subject |
mass spectrometry |
|
dc.subject |
MTT assay |
|
dc.subject |
nonhuman |
|
dc.subject |
nuclear magnetic resonance |
|
dc.subject |
Xylariales |
|
dc.subject |
animal |
|
dc.subject |
chemistry |
|
dc.subject |
HCT 116 cell line |
|
dc.subject |
HT-29 cell line |
|
dc.subject |
human |
|
dc.subject |
metabolism |
|
dc.subject |
mouse |
|
dc.subject |
nuclear magnetic resonance spectroscopy |
|
dc.subject |
preclinical study |
|
dc.subject |
RAW 264.7 cell line |
|
dc.subject |
Animals |
|
dc.subject |
Anti-Inflammatory Agents |
|
dc.subject |
Antineoplastic Agents |
|
dc.subject |
Biological Products |
|
dc.subject |
Drug Evaluation, Preclinical |
|
dc.subject |
HCT116 Cells |
|
dc.subject |
HT29 Cells |
|
dc.subject |
Humans |
|
dc.subject |
Lipopolysaccharides |
|
dc.subject |
Magnetic Resonance Spectroscopy |
|
dc.subject |
Mice |
|
dc.subject |
Molecular Structure |
|
dc.subject |
Nitric Oxide |
|
dc.subject |
RAW 264.7 Cells |
|
dc.subject |
Xylariales |
|
dc.title |
Anti-inflammatory and cytotoxic agents from Xylaria sp. SWUF09-62 fungus |
|
dc.type |
Article |
|
dc.rights.holder |
Scopus |
|
dc.identifier.bibliograpycitation |
Natural Product Research. Vol 35, No.12 (2021), p.2010-2019 |
|
dc.identifier.doi |
10.1080/14786419.2019.1652292 |
|